The neurochemistry of vascular dementia
- PMID: 8087172
- DOI: 10.1159/000106715
The neurochemistry of vascular dementia
Abstract
Vascular dementia (VAD) is cognitive impairment caused by changes in the blood circulation of the brain. It is not synonymous with multi-infarct dementia. The latter is a subgroup of VAD. Neurochemical investigations of noninfarcted brain tissue from patients with VAD show general changes in VAD brains. The serotonin metabolism is severely reduced and so is the activity of choline acetyltransferase. Monamine oxidase B is significantly increased in the white matter. A severe decrease in myelin components indicates white matter disturbances of such a degree that they must be considered to be of pathogenetic importance. The levels of some neuropeptides in the hypothalamus are increased. This is a finding which is in agreement with clinical findings of a high activity in the hypothalamic-pituitary-adrenal axis in patients with VAD. This high activity is possibly due to a loss of serotonergic inhibitory tone on the hypothalamus in VAD brains.
Similar articles
-
White matter damage is associated with matrix metalloproteinases in vascular dementia.Stroke. 2001 May;32(5):1162-8. doi: 10.1161/01.str.32.5.1162. Stroke. 2001. PMID: 11340226
-
Pathogenetic basis of vascular dementia.Alzheimer Dis Assoc Disord. 1991 Summer;5(2):91-102. doi: 10.1097/00002093-199100520-00006. Alzheimer Dis Assoc Disord. 1991. PMID: 2059412 Review.
-
Imaging of static brain lesions in vascular dementia: implications for clinical trials.Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13 Suppl 3:S81-90. Alzheimer Dis Assoc Disord. 1999. PMID: 10609686 Review.
-
Vascular dementia: neuropathologic alterations and metabolic brain changes.J Neurol Sci. 1992 Jun;109(2):121-31. doi: 10.1016/0022-510x(92)90158-h. J Neurol Sci. 1992. PMID: 1634894 Review.
-
Diagnosis and management of vascular cognitive impairment and dementia.J Neural Transm Suppl. 2002;(63):91-109. doi: 10.1007/978-3-7091-6137-1_6. J Neural Transm Suppl. 2002. PMID: 12597611 Review.
Cited by
-
(-)-SCR1693 Protects against Memory Impairment and Hippocampal Damage in a Chronic Cerebral Hypoperfusion Rat Model.Sci Rep. 2016 Jun 28;6:28908. doi: 10.1038/srep28908. Sci Rep. 2016. PMID: 27349344 Free PMC article.
-
Dopamine differently modulates central cholinergic circuits in patients with Alzheimer disease and CADASIL.J Neural Transm (Vienna). 2014 Oct;121(10):1313-20. doi: 10.1007/s00702-014-1195-1. Epub 2014 Mar 28. J Neural Transm (Vienna). 2014. PMID: 24677024
-
Recent updates on subcortical ischemic vascular dementia.J Stroke. 2014 Jan;16(1):18-26. doi: 10.5853/jos.2014.16.1.18. Epub 2014 Jan 31. J Stroke. 2014. PMID: 24741561 Free PMC article. Review.
-
MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia.AJNR Am J Neuroradiol. 2002 Jan;23(1):27-32. AJNR Am J Neuroradiol. 2002. PMID: 11827872 Free PMC article.
-
Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.CNS Drugs. 2003;17(12):905-14. doi: 10.2165/00023210-200317120-00004. CNS Drugs. 2003. PMID: 12962529 Clinical Trial.